Larry Glass - Neuren Pharmaceuticals Insider

Neuren Pharmaceuticals Limited -- USA Stock  

USD 2.35  0.03  1.26%

CEO, Managing Director

Mr. Larry Glass was Chief Science Officer and Executive Director of Neuren Pharmaceuticals Limited since September 2, 2013. He is a seasoned manager with more than 30 years in the life sciences industry. Before he joined Neuren, he worked as an independent consultant for a number of biotech companies in the US and internationally, providing management, strategic and business development services. Prior to that, he was CEO of a contract research organisation that provided preclinical research and clinical trials support for major pharmaceutical and biotechnology companies and the US government. For a number of years, the CRO operated as a subsidiary of a NYSElisted company and was subsequently sold to a European biopharmaceutical enterprise which was then acquired by Johnson Johnson.
  CEO Since 2013      
61 3 9092 0480

Management Efficiency

The company has return on total asset (ROA) of (34.89) % which means that it has lost $34.89 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of (18.93) % meaning that it generated substantial loss on money invested by shareholders.

Similar Executives

Found 2 records

CEO Since

Gillian TansBooking Holdings Inc
Glenn FogelBooking Holdings Inc

Entity Summary

Neuren Pharmaceuticals Limited, a biopharmaceutical company, focuses on the development of therapies for brain injury, neurodevelopment, and neurodegenerative disorders. Neuren Pharmaceuticals Limited was incorporated in 1993 and is based in Port Melbourne, Australia. Neuren Pharmaceuticals is traded on OTC Market in USA.Neuren Pharmaceuticals Limited (NURPF) is traded on OTC Market in USA. It is located in 435 Williamstown Road and employs 10 people.

Did you try this?

Run Risk-Return Analysis Now

Risk-Return Analysis

View associations between returns expected from investment and the risk you assume
Hide  View All  NextLaunch Risk-Return Analysis
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Neuren Pharmaceuticals Limited to your portfolio

Top Management

Neuren Pharmaceuticals Leadership Team
Joseph Horrigan, VP
Larry Glass, CEO
Bruce Hancox, Director
James Shaw, COO
Richard Treagus, Chairman, Ph.D
Trevor Scott, Director, Ph.D
Jon Pilcher, CFO

Stock Performance

Neuren Pharmaceuticals Performance Indicators